By Sabela Ojea IGC Pharma said its Alzheimer's disease drug candidate TGR-63 demonstrated enhanced memory function in preclinical studies. The pharmaceutical.
Biogen is halting the development and commercialization of the Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to.
By Denny Jacob Annovis Bio shares retreated 13% to $10.16 in premarket trading following a delay in releasing study data for buntanetap in Parkinson's.